Investors

OvaScience is a global fertility company dedicated to improving treatment options for women around the world.

OVAS (Common Stock)
Price & Exchange
$1.45
NASDAQ
Change (%)
 Stock is Up 0.01 (0.69%)
Volume
208,680
02/23/17      4:00 p.m. ET

Minimum 20 minute delay
Refresh quote

Investor Overview

Recent News

More »
DateTitle 
02/23/17OvaScience to Host Fourth Quarter and Fiscal Year 2016 Financial Results Conference Call
WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 23, 2017-- OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it will host a conference call at 4:30 p.m. ET on Thursday, March 2, 2017 to discuss fourth quarter and fiscal year 2016 financial results and provide a general corporate update. The live call can be accessed by dialing +1-888-424-... 
Printer Friendly Version
01/05/17OvaScience to Present at the 35th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass.--(BUSINESS WIRE)--Jan. 5, 2017-- OvaScience℠ (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced that Michelle Dipp, M.D., Ph.D., Executive Chair and Co-founder of OvaScience, will present a corporate overview at the 35th Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2017 at 8:30 a.m. PT (11:30 a.m. ET) at the Westin St. ... 
Printer Friendly Version
12/23/16OvaScience Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass.--(BUSINESS WIRE)--Dec. 23, 2016-- OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced the grant of inducement awards to purchase an aggregate of 356,000 shares of its common stock to 16 newly hired employees. In connection with the Company’s previously announced corporate restructuring, the Company expects that 278,000 of these option... 
Printer Friendly Version
12/21/16OvaScience Announces Business Update
– Maintaining AUGMENT Commercial Footprint; Increasing Focus on OvaPrime and OvaTure – – Improving Cost Structure Through Corporate Restructuring; Extending Cash Runway to Q1 2019 – – Chief Executive Officer Harald Stock, Ph.D., Hired to Lead Commercial Expansion, Stepping Down – WALTHAM, Mass.--(BUSINESS WIRE)--Dec. 21, 2016-- OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, deve... 
Printer Friendly Version

Upcoming Events

More »
DateTitle
03/02/17 4:30 p.m. ET
Q4 2016 Ovascience Inc Earnings Conference Call
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources